Effectiveness of triplet chemotherapy plus bevacizumab intensive regimen (FIr-B/FOx) and secondary liver surgery according to KRAS genotype in metastatic colorectal cancer (MCRC).
G. Bruera
No relevant relationships to disclose
K. Cannita
No relevant relationships to disclose
D. Di Giacomo
No relevant relationships to disclose
G. Troncone
No relevant relationships to disclose
A. Marchetti
No relevant relationships to disclose
G. Coletti
No relevant relationships to disclose
J. Sabourin
No relevant relationships to disclose
M. Tosi
No relevant relationships to disclose
C. Ficorella
No relevant relationships to disclose
E. Ricevuto
No relevant relationships to disclose